Short Interest in LifeStance Health Group, Inc. (NASDAQ:LFST) Declines By 10.1%

LifeStance Health Group, Inc. (NASDAQ:LFST) was the target of a large decrease in short interest in December. As of December 31st, there was short interest totalling 9,860,000 shares, a decrease of 10.1% from the December 15th total of 10,970,000 shares. Based on an average daily volume of 1,460,000 shares, the short-interest ratio is currently 6.8 days. Approximately 8.9% of the shares of the stock are short sold.

LifeStance Health Group Trading Up 0.1 %

Shares of NASDAQ:LFST opened at $7.99 on Friday. The company’s fifty day moving average price is $7.44 and its 200-day moving average price is $6.72. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.32 and a quick ratio of 1.32. LifeStance Health Group has a one year low of $4.64 and a one year high of $9.20.

LifeStance Health Group (NASDAQ:LFST) last released its earnings results on Thursday, November 7th. The company reported ($0.02) EPS for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.05. LifeStance Health Group had a negative return on equity of 6.66% and a negative net margin of 7.90%. The business had revenue of $312.70 million for the quarter, compared to analysts’ expectations of $302.25 million. During the same quarter in the prior year, the firm earned ($0.17) earnings per share. The firm’s revenue was up 18.9% on a year-over-year basis. As a group, analysts anticipate that LifeStance Health Group will post -0.2 EPS for the current year.

Insider Buying and Selling

In other LifeStance Health Group news, Director Robert Bessler sold 75,000 shares of the stock in a transaction that occurred on Wednesday, November 27th. The shares were sold at an average price of $7.54, for a total value of $565,500.00. Following the sale, the director now directly owns 1,424,447 shares in the company, valued at $10,740,330.38. This represents a 5.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 6.60% of the stock is currently owned by insiders.

Hedge Funds Weigh In On LifeStance Health Group

A number of large investors have recently modified their holdings of the company. Wellington Management Group LLP boosted its stake in LifeStance Health Group by 15.2% in the third quarter. Wellington Management Group LLP now owns 4,830,441 shares of the company’s stock worth $33,813,000 after buying an additional 638,385 shares in the last quarter. Principal Financial Group Inc. boosted its stake in shares of LifeStance Health Group by 6.1% in the 3rd quarter. Principal Financial Group Inc. now owns 4,116,766 shares of the company’s stock valued at $28,817,000 after purchasing an additional 235,316 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of LifeStance Health Group by 26.8% during the 3rd quarter. Geode Capital Management LLC now owns 3,452,178 shares of the company’s stock valued at $24,170,000 after purchasing an additional 729,794 shares during the last quarter. State Street Corp raised its position in LifeStance Health Group by 4.7% in the 3rd quarter. State Street Corp now owns 2,750,656 shares of the company’s stock worth $19,255,000 after purchasing an additional 122,844 shares during the period. Finally, Jennison Associates LLC raised its position in LifeStance Health Group by 9.5% in the 3rd quarter. Jennison Associates LLC now owns 2,136,942 shares of the company’s stock worth $14,959,000 after purchasing an additional 184,896 shares during the period. 85.50% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on LFST shares. The Goldman Sachs Group upgraded LifeStance Health Group from a “neutral” rating to a “buy” rating and set a $10.00 price objective on the stock in a research report on Monday, December 16th. Barclays upped their target price on LifeStance Health Group from $6.00 to $7.00 and gave the stock an “underweight” rating in a research note on Monday, November 11th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat.com, LifeStance Health Group presently has an average rating of “Hold” and an average price target of $8.70.

About LifeStance Health Group

LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.